Last 7 days
-5.6%
Last 30 days
-3.4%
Last 90 days
43.3%
Trailing 12 Months
39.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 135.3B | 26.3B | -2.97% | 16.81% | 19.8 | 5.14 | 2.18% | 21.86% |
GILD | 105.0B | 27.1B | -0.99% | 30.15% | 31.49 | 3.87 | -1.26% | -54.91% |
MRNA | 73.3B | 21.4B | 7.28% | 27.41% | 6.23 | 3.43 | 80.80% | 66.62% |
BIIB | 41.9B | 10.4B | 5.85% | 32.49% | 14.62 | 4.04 | -6.64% | 85.32% |
NBIX | 10.4B | 1.4B | -8.79% | 49.41% | 178.74 | 7.49 | 29.86% | -86.92% |
MID-CAP | ||||||||
DNLI | 3.9B | - | 18.31% | 0.06% | -12.88 | 32.03 | -41.50% | -1123.42% |
BEAM | 3.2B | - | 23.33% | -24.11% | -10.12 | 59.51 | 215916.67% | 21.41% |
SMALL-CAP | ||||||||
RCUS | 1.7B | 432.8M | 17.41% | -21.00% | 20.97 | 3.87 | 1042.97% | 128.67% |
BBIO | 1.4B | - | 35.16% | 1.79% | -2.74 | 20.84 | 745.14% | 12.80% |
REPL | 1.3B | 3.1M | -3.43% | 39.57% | -8.78 | 417.83 | 7.05% | -46.74% |
NVAX | 886.0M | 1.8B | 24.61% | -84.52% | -0.67 | 0.48 | 53.41% | -22.97% |
FATE | 574.9M | 69.0M | -39.96% | -83.45% | -1.96 | 8.33 | 26.22% | -49.52% |
SGMO | 565.8M | 112.1M | 28.78% | -35.14% | -3.18 | 5.05 | 3.26% | 1.99% |
VXRT | 142.4M | - | 42.67% | -74.19% | -1.36 | 418.24 | -71.03% | -64.56% |
IBIO | 6.7M | - | 67.66% | -93.12% | -0.11 | 3.21 | 0.51% | -141.69% |
Income Statement (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Revenue | -4.7% | 3,082 | 3,233 | 3,170 | 3,062 | 2,879 |
Operating Expenses | 9.4% | 144,141 | 131,809 | 118,314 | 108,510 | 99,087 |
S&GA Expenses | 8.2% | 44,740 | 41,340 | 38,769 | 34,476 | 30,084 |
R&D Expenses | 9.9% | 99,401 | 90,469 | 79,545 | 74,034 | 69,003 |
Interest Expenses | -100.0% | 0 | 1.00 | 248 | - | - |
Net Income | -10.3% | -146,725.00 | -133,023.00 | -118,036.00 | -107,884.00 | -99,993.00 |
Net Income Margin | -15.7% | -47.61* | -41.13* | -37.22* | -35.22* | - |
Free Cahsflow | -10.2% | -110,651.00 | -100,434.00 | -84,516.00 | -77,705.00 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Assets | -5.1% | 436 | 459 | 461 | 485 | 503 |
Current Assets | -5.6% | 379 | 402 | 404 | 428 | 444 |
Cash Equivalents | -20.8% | 89 | 112 | 106 | 132 | 162 |
Net PPE | -4.3% | 8 | 8 | 8 | 7 | 7 |
Liabilities | 5.8% | 52 | 49 | 50 | 48 | 46 |
Current Liabilities | 15.9% | 24 | 20 | 21 | 18 | 17 |
Shareholder's Equity | -6.4% | 384 | 410 | 411 | 438 | 457 |
Retained Earnings | -12.2% | -396.60 | -353.50 | -311.20 | -279.51 | -249.83 |
Additional Paid-In Capital | 1.9% | 778 | 763 | 723 | 717 | 707 |
Shares Outstanding | 0.9% | 50 | 49 | 47 | 47 | 52 |
Float | - | 620 | - | - | - | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Cashflow From Operations | -10.5% | -107.57 | -97.32 | -82.18 | -75.75 | -70.39 |
Share Based Compensation | 2.7% | 26 | 25 | 24 | 22 | 19 |
Cashflow From Investing | 47.2% | -12.39 | -23.48 | -1.81 | -123.75 | -78.91 |
Cashflow From Financing | 16.5% | 44 | 38 | 7 | 7 | 265 |
95.4%
94.1%
88.7%
Y-axis is the maximum loss one would have experienced if Replimune Group was unfortunately bought at previous high price.
13.1%
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-01-26 | STRS OHIO | unchanged | - | 42,000 | 116,000 | -% |
2023-01-24 | Moody Aldrich Partners LLC | new | - | 2,487,090 | 2,487,090 | 0.50% |
2023-01-20 | HARBOR CAPITAL ADVISORS, INC. | reduced | -2.11 | 259,059 | 736,059 | 0.71% |
2023-01-13 | Allworth Financial LP | unchanged | - | 354 | 354 | -% |
2023-01-12 | Hennion & Walsh Asset Management, Inc. | added | 14.47 | 427,000 | 960,000 | 0.06% |
2022-11-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 13.22 | 68,000 | 641,000 | -% |
2022-11-16 | BNP PARIBAS ARBITRAGE, SNC | added | 538.73 | 593,264 | 704,979 | -% |
2022-11-15 | STATE STREET CORP | reduced | -12.11 | -3,801,000 | 25,072,000 | -% |
2022-11-15 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
2022-11-15 | ALLIANCEBERNSTEIN L.P. | unchanged | - | -6,000 | 532,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Nov 18, 2022 | redmile group, llc | 9.9% | 5,165,131 | SC 13G/A | |
Sep 14, 2022 | atlas venture fund x, l.p. | 4.4% | 2,164,037 | SC 13D/A | |
Feb 14, 2022 | redmile group, llc | 9.9% | 4,775,461 | SC 13G/A | |
Feb 14, 2022 | omega fund iv, l.p. | 10.6% | 5,012,052 | SC 13G/A | |
Feb 14, 2022 | price t rowe associates inc /md/ | 12.5% | 5,868,638 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Jul 12, 2021 | price t rowe associates inc /md/ | 10.8% | 5,069,450 | SC 13G/A | |
Feb 16, 2021 | bain capital life sciences fund, l.p. | 0% | 0 | SC 13G/A | |
Feb 16, 2021 | price t rowe associates inc /md/ | 5.7% | 2,625,691 | SC 13G | |
Feb 16, 2021 | forbion capital fund iii cooperatief u.a. | 11.13% | 5,115,121 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Jan 04, 2023 | 8-K | Current Report | |
Dec 13, 2022 | 4 | Insider Trading | |
Dec 12, 2022 | 424B5 | Prospectus Filed | |
Dec 12, 2022 | 8-K | Current Report | |
Dec 07, 2022 | 8-K | Current Report | |
Dec 07, 2022 | 424B5 | Prospectus Filed | |
Dec 06, 2022 | SC 13D/A | 13D - Major Acquisition | |
Dec 05, 2022 | 3 | Insider Trading | |
Dec 05, 2022 | 4 | Insider Trading | |
Nov 18, 2022 | SC 13G/A | Major Ownership Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2022-12-09 | Esposito Pamela | acquired | 15,150 | 1.01 | 15,000 | chief business officer |
2022-12-09 | Esposito Pamela | sold | -375,450 | 25.03 | -15,000 | chief business officer |
2022-12-01 | Xynos Konstantinos | acquired | - | - | 17,500 | chief medical officer |
2022-05-16 | Patel Sushil | sold | -155,923 | 14.59 | -10,687 | chief commercial officer |
2022-05-16 | Esposito Pamela | sold | -51,167.1 | 14.59 | -3,507 | chief business officer |
2022-05-16 | Love Colin | sold | -92,267.2 | 14.59 | -6,324 | chief operating officer |
2022-05-16 | Lewis Tanya | sold | -79,851.1 | 14.59 | -5,473 | chief dev. op officer |
2022-05-16 | Coffin Robert | sold | -83,702.8 | 14.59 | -5,737 | president & chief r&d officer |
2022-05-16 | Astley-Sparke Philip | sold | -140,531 | 14.59 | -9,632 | chief executive officer |
2022-05-16 | Franchi Jean M. | sold | -50,131.2 | 14.59 | -3,436 | chief financial officer |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Operating expenses: | ||||
Research and development | $ 28,834 | $ 19,902 | $ 58,312 | $ 38,456 |
Selling, general and administrative | 12,745 | 9,345 | 24,143 | 18,172 |
Total operating expenses | 41,579 | 29,247 | 82,455 | 56,628 |
Loss from operations | (41,579) | (29,247) | (82,455) | (56,628) |
Other income (expense): | ||||
Research and development incentives | 574 | 725 | 1,425 | 1,513 |
Investment income | 1,112 | 80 | 1,455 | 172 |
Interest expense on finance lease liability | (550) | (557) | (1,102) | (1,115) |
Other (expense) income | (2,659) | (356) | (4,678) | (608) |
Total other (expense) income, net | (1,523) | (108) | (2,900) | (38) |
Net loss | $ (43,102) | $ (29,355) | $ (85,355) | $ (56,666) |
Net loss per share attributable to common stockholders, basic (in dollars per share) | $ (0.79) | $ (0.56) | $ (1.57) | $ (1.09) |
Net loss per share attributable to common stockholders, diluted (in dollars per share) | $ (0.79) | $ (0.56) | $ (1.57) | $ (1.09) |
Weighted average common shares outstanding, basic (in shares) | 54,770,291 | 52,081,325 | 54,492,395 | 51,962,795 |
Weighted average common shares outstanding, diluted (in shares) | 54,770,291 | 52,081,325 | 54,492,395 | 51,962,795 |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2022 | Mar. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 88,930 | $ 105,948 |
Short-term investments | 282,890 | 289,707 |
Research and development incentives receivable | 2,589 | 3,055 |
Prepaid expenses and other current assets | 4,981 | 5,267 |
Total current assets | 379,390 | 403,977 |
Property, plant and equipment, net | 7,910 | 7,933 |
Research and development incentives receivable, non-current | 1,296 | 0 |
Restricted cash | 1,636 | 1,636 |
Right-to-use asset - operating leases | 4,984 | 5,552 |
Right-to-use asset - financing leases | 40,879 | 42,094 |
Total assets | 436,095 | 461,192 |
Current liabilities: | ||
Accounts payable | 3,996 | 3,732 |
Accrued expenses and other current liabilities | 15,939 | 13,392 |
Operating lease liabilities, current | 1,002 | 1,070 |
Financing lease liabilities, current | 2,600 | 2,562 |
Total current liabilities | 23,537 | 20,756 |
Operating lease liabilities, non-current | 4,280 | 4,801 |
Financing lease liabilities, non-current | 24,206 | 24,406 |
Total liabilities | 52,023 | 49,963 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity | ||
Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2022 and March 31, 2022; 49,739,407 and 47,338,660 shares issued and outstanding as of September 30, 2022 and March 31, 2022, respectively | 50 | 47 |
Additional paid-in capital | 777,650 | 723,359 |
Accumulated deficit | (396,559) | (311,204) |
Accumulated other comprehensive income (loss) | 2,931 | (973) |
Total stockholders' equity | 384,072 | 411,229 |
Total liabilities and stockholders' equity | $ 436,095 | $ 461,192 |